FORA Capital LLC Makes New $413,000 Investment in Bruker Co. (NASDAQ:BRKR)

FORA Capital LLC purchased a new stake in Bruker Co. (NASDAQ:BRKR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,053 shares of the medical research company's stock, valued at approximately $413,000.

Several other institutional investors and hedge funds also recently made changes to their positions in BRKR. Barclays PLC increased its stake in shares of Bruker by 36.5% in the third quarter. Barclays PLC now owns 55,685 shares of the medical research company's stock valued at $3,847,000 after buying an additional 14,888 shares during the period. GAMMA Investing LLC increased its stake in shares of Bruker by 47.5% in the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after buying an additional 412 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Bruker by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company's stock valued at $779,000 after buying an additional 177 shares during the period. Eagle Bay Advisors LLC increased its stake in shares of Bruker by 2,324.1% in the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock valued at $41,000 after buying an additional 674 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of Bruker by 11.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 115,508 shares of the medical research company's stock valued at $6,771,000 after purchasing an additional 11,860 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Stock Performance

NASDAQ:BRKR traded up $0.46 during trading hours on Friday, reaching $37.15. The stock had a trading volume of 665,314 shares, compared to its average volume of 1,600,698. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The stock has a 50 day simple moving average of $40.49 and a 200 day simple moving average of $50.65. Bruker Co. has a 12-month low of $34.10 and a 12-month high of $79.78. The stock has a market cap of $5.63 billion, a P/E ratio of 48.90, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.01. The company had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The firm's quarterly revenue was up 11.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.53 earnings per share. On average, research analysts forecast that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.54%. The ex-dividend date was Monday, March 17th. Bruker's dividend payout ratio is 38.46%.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several research analyst reports. Guggenheim restated a "buy" rating on shares of Bruker in a research report on Monday, February 24th. The Goldman Sachs Group cut their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Citigroup cut their target price on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Stifel Nicolaus cut their price target on Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a report on Thursday, May 8th. Finally, Wells Fargo & Company cut their price target on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $60.10.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.